Home
YMAB
YMAB News

Latest Y-mAbs Therapeutics Inc. (YMAB) News on December 18, 2024

Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks

TipRanks

3 days ago

Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

GlobeNewswire

11 days ago

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

MT Newswires

13 days ago

Brookline Capital Initiates Y-mAbs Therapeutics at Buy With $17 Price Target

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

GlobeNewswire

21 days ago

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

MT Newswires

a month ago

Oppenheimer Initiates Coverage on Y-mAbs Therapeutics With Outperform Rating, $23 Price Target

Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth

Simply Wall St.

a month ago

Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth

GuruFocus.com

a month ago

Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

Zacks

a month ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire

a month ago

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings

GuruFocus.com

a month ago

What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings

Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a month ago

Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

GlobeNewswire

a month ago

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know

Zacks

2 months ago

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

GlobeNewswire

2 months ago

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

GuruFocus.com

2 months ago

Y-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ...

Y-mAbs to Participate in Upcoming Investor Conferences in October

GlobeNewswire

3 months ago

Y-mAbs to Participate in Upcoming Investor Conferences in October

While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate

Simply Wall St.

3 months ago

While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate

MT Newswires

3 months ago

Y-mAbs Therapeutics Signs Lease Deal for New Jersey Property

MT Newswires

3 months ago

Y-mAbs Therapeutics' Neuroblastoma Drug Shows Consistent Disease Control in Clinical Study

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

GlobeNewswire

3 months ago

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

Y-mAbs to Participate in Upcoming Investor Conferences in September

GlobeNewswire

3 months ago

Y-mAbs to Participate in Upcoming Investor Conferences in September

MT Newswires

4 months ago

Cantor Fitzgerald Initiates Coverage on Y-mAbs Therapeutics With Overweight Rating, $20 Price Target

Why Y-mAbs Therapeutics Stock Got Mashed on Monday

Motley Fool

4 months ago

Why Y-mAbs Therapeutics Stock Got Mashed on Monday

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates

Zacks

4 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire

4 months ago

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners’ Top Holdings Now?

Insider Monkey

4 months ago

Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners’ Top Holdings Now?

Y-mAbs to Participate in Upcoming Investor Conferences in August

GlobeNewswire

4 months ago

Y-mAbs to Participate in Upcoming Investor Conferences in August

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

GlobeNewswire

4 months ago

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Simply Wall St.

5 months ago

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

MT Newswires

6 months ago

Y-mAbs Therapeutics Appoints Peter Pfreundschuh as CFO

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

GlobeNewswire

6 months ago

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

MT Newswires

6 months ago

Truist Initiates Y-mAbs Therapeutics at Buy With $21 Price Target, Calls Radioimmunotherapy Platform 'Undervalued'

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

6 months ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

6 months ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

6 months ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

6 months ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

6 months ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

6 months ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Reuters

6 months ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

GlobeNewswire

6 months ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional investors' interest

Simply Wall St.

6 months ago

With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional investors' interest

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

GlobeNewswire

6 months ago

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

GlobeNewswire

6 months ago

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

GlobeNewswire

7 months ago

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

GlobeNewswire

7 months ago

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript

Insider Monkey

7 months ago

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript

GuruFocus.com

7 months ago

Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

Thomson Reuters StreetEvents

7 months ago

Q1 2024 Y-mAbs Therapeutics Inc Earnings Call

Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates

GuruFocus.com

7 months ago

Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates

Zacks

7 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire

7 months ago

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

GlobeNewswire

8 months ago

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

Y-mAbs to Present at 2024 ASCO Annual Meeting

GlobeNewswire

8 months ago

Y-mAbs to Present at 2024 ASCO Annual Meeting

Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%

Simply Wall St.

8 months ago

Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%

Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet

Zacks

9 months ago

Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet

YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?

Zacks

9 months ago

YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

GlobeNewswire

9 months ago

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?

Zacks

9 months ago

Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?

Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice

Zacks

9 months ago

Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript

Insider Monkey

9 months ago

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

GlobeNewswire

9 months ago

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

Y-mAbs Therapeutics Full Year 2023 Earnings: Beats Expectations

Simply Wall St.

10 months ago

Y-mAbs Therapeutics Full Year 2023 Earnings: Beats Expectations

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Y-mAbs Therapeutics Inc Earnings Call

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates

Zacks

10 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates

GuruFocus.com

10 months ago

Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

GlobeNewswire

10 months ago

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline

Zacks

10 months ago

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline

CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last?

Zacks

10 months ago

CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last?

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

GlobeNewswire

10 months ago

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?

Zacks

10 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?

Thomson Reuters StreetEvents

a year ago

Q4 2023 Whirlpool Corp Earnings Call

Here's Why We're Not At All Concerned With Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Not At All Concerned With Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation

Invesco Closed-End Funds Declare Dividends

PR Newswire

a year ago

Invesco Closed-End Funds Declare Dividends

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

GlobeNewswire

a year ago

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

i-80 Gold Reports High-Grade Drill Results from the FAD Deposit at Ruby Hill

CNW Group

a year ago

i-80 Gold Reports High-Grade Drill Results from the FAD Deposit at Ruby Hill

CENTERSPACE ANNOUNCES 2023 DIVIDEND ALLOCATIONS

PR Newswire

a year ago

CENTERSPACE ANNOUNCES 2023 DIVIDEND ALLOCATIONS

TrustCo’s Total Loans Surpass $5 Billion - Reach All-Time High; Nonperforming Assets to Total Assets at 0.29%, Lowest in 17 Years

GlobeNewswire

a year ago

TrustCo’s Total Loans Surpass $5 Billion - Reach All-Time High; Nonperforming Assets to Total Assets at 0.29%, Lowest in 17 Years

The Return Trends At DHT Holdings (NYSE:DHT) Look Promising

Simply Wall St.

a year ago

The Return Trends At DHT Holdings (NYSE:DHT) Look Promising

AdvanSix Provides Update on Plant Production Rates

Business Wire

a year ago

AdvanSix Provides Update on Plant Production Rates

CENTERSPACE ANNOUNCES FOURTH QUARTER 2023 EARNINGS RELEASE DATE

PR Newswire

a year ago

CENTERSPACE ANNOUNCES FOURTH QUARTER 2023 EARNINGS RELEASE DATE

Vital Farms Inc President and CEO Russell Diez-Canseco Sells 27,560 Shares

GuruFocus.com

a year ago

Vital Farms Inc President and CEO Russell Diez-Canseco Sells 27,560 Shares

i-80 Gold Announces High-Grade Results from Hilltop Drilling at Ruby Hill

PR Newswire

a year ago

i-80 Gold Announces High-Grade Results from Hilltop Drilling at Ruby Hill

Runway Growth Finance Corp. Announces Date for Fourth Quarter and Full Year 2023 Financial Results and Conference Call

GlobeNewswire

a year ago

Runway Growth Finance Corp. Announces Date for Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Procaps Group – Notice to Shareholders

Business Wire

a year ago

Procaps Group – Notice to Shareholders

AdvanSix to Release Fourth Quarter Financial Results and Hold Investor Conference Call on February 16

Business Wire

a year ago

AdvanSix to Release Fourth Quarter Financial Results and Hold Investor Conference Call on February 16

Centrus Energy Corp. (LEU) Soars 7.9%: Is Further Upside Left in the Stock?

Zacks

a year ago

Centrus Energy Corp. (LEU) Soars 7.9%: Is Further Upside Left in the Stock?

Reuters

a year ago

UPDATE 1-US seeks to jump-start production of higher-energy uranium now made in Russia

Reuters

a year ago

US seeks to jump-start production of higher-energy uranium now made in Russia

Universal Stainless (USAP) Surges 76% in 3 Months: Here's Why

Zacks

a year ago

Universal Stainless (USAP) Surges 76% in 3 Months: Here's Why

i-80 Provides 2023 Summary & 2024 Plans - Highlighting Numerous Achievements & Catalysts

PR Newswire

a year ago

i-80 Provides 2023 Summary & 2024 Plans - Highlighting Numerous Achievements & Catalysts

Investors in Universal Logistics Holdings (NASDAQ:ULH) have seen respectable returns of 50% over the past five years

Simply Wall St.

a year ago

Investors in Universal Logistics Holdings (NASDAQ:ULH) have seen respectable returns of 50% over the past five years

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

GlobeNewswire

a year ago

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

Why LifeMD's CEO isn't concerned about Eli Lilly's DTC site

Yahoo Finance Video

a year ago

Why LifeMD's CEO isn't concerned about Eli Lilly's DTC site

New Found Increases Queensway Drill Program to 650,000 Metres, Seismic Interpretation to Guide 2024 Targeting

Business Wire

a year ago

New Found Increases Queensway Drill Program to 650,000 Metres, Seismic Interpretation to Guide 2024 Targeting

TDCX Inc. Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Remaining Outstanding Class A Ordinary Shares of the Company

Business Wire

a year ago

TDCX Inc. Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Remaining Outstanding Class A Ordinary Shares of the Company

Pennant and John Muir Health Enter into a Home Health Joint Venture in the Bay Area, California

GlobeNewswire

a year ago

Pennant and John Muir Health Enter into a Home Health Joint Venture in the Bay Area, California

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Business Wire

a year ago

Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is definitely on the radar of institutional investors who own 40% of the company

Simply Wall St.

a year ago

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is definitely on the radar of institutional investors who own 40% of the company

Procaps Group Reports Third Quarter 2023 Results

Business Wire

a year ago

Procaps Group Reports Third Quarter 2023 Results

Share on Social Networks: